|
HNRPLL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.8429000004967E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.55700000000048E-05 |
| Normal-vs-Stage2 |
4.24629999999926E-05 |
| Normal-vs-Stage3 |
1.78867999999222E-05 |
| Normal-vs-Stage4 |
6.21359999999349E-05 |
| Stage1-vs-Stage2 |
8.299800E-02 |
| Stage1-vs-Stage3 |
1.450600E-01 |
| Stage1-vs-Stage4 |
2.803200E-01 |
| Stage2-vs-Stage3 |
4.374400E-01 |
| Stage2-vs-Stage4 |
5.502200E-01 |
| Stage3-vs-Stage4 |
9.416000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.14669999945671E-07 |
| Normal-vs-AfricanAmerican |
1.526990E-01 |
| Normal-vs-Asian |
9.942200E-03 |
| Caucasian-vs-AfricanAmerican |
7.651600E-02 |
| Caucasian-vs-Asian |
3.039800E-01 |
| AfricanAmerican-vs-Asian |
4.528000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.72219999991808E-07 |
| Normal-vs-Female |
1.51387999999253E-05 |
| Male-vs-Female |
2.184800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.162100E-04 |
| Normal-vs-Age(41-60Yrs) |
2.20819999996458E-06 |
| Normal-vs-Age(61-80Yrs) |
7.62969999956731E-07 |
| Normal-vs-Age(81-100Yrs) |
1.075830E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.778810E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.716100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.334000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.995000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.297800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.943400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.037200E-01 |
| Classical-VS-Follicular |
3.477500E-02 |
| Classical-VS-Other |
6.176600E-01 |
| Classical-VS-Normal |
6.038000E-04 |
| Tall-VS-Follicular |
7.292800E-01 |
| Tall-VS-Other |
8.648400E-01 |
| Tall-VS-Normal |
1.379180E-04 |
| Follicular-VS-Other |
7.871000E-01 |
| Follicular-VS-Normal |
1.94079999999985E-05 |
| Other-VS-Normal |
7.260400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.43139999997377E-06 |
| Normal-vs-N1 |
7.93530000000597E-05 |
| N0-vs-N1 |
8.988200E-01 |
|
|
